The risk of nonarteritic anterior ischemic optic neuropathy (NAION) was not significantly different among those on GLP-1 drugs and those on other diabetes medicines
about 50 percent lost at least 20 percent
However, high doses may worsen it over time
First, pre-existing conditions in those organ systems may represent contraindications or risk factors that affect whether GLP-1 therapy is appropriate for you
This means that while our bodies can produce it under normal conditions, certain circumstancessuch as intense physical stress, injury, or illnessmay necessitate additional intake
En marzo, Wegovy, de Novo Nordisk, se convirti en el primer medicamento para adelgazar aprobado tambin para ayudar a prevenir problemas cardiacos graves en personas con enfermedades cardiovasculares